Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Phase 2RecruitingNCT04803318

Second Affiliated Hospital of Guangzhou Medical University100 enrolled

Overview

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Solid Tumor, Adult Hepatocellular Carcinoma

Interventions

Combination of three inhibitors Trametinib, Everolimus and LenvatinibDRUG

Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recurrent/Refractory advanced solid tumors * Age between 18 and 85 years * Expected life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical commodities * others

Locations (1)

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.

Time frame: up to 36 months

Secondary Outcomes

Assessing progress free survival

Time frame: 48 months

Assessing overall survival

Assessing overall time to survival.

Time frame: 48 months

Central Contacts

Zhenfeng Zhang, MD, PhD

CONTACT

+862039195966 zhangzhf@gzhmu.edu.cn

Bingjia He, MD

CONTACT

+862039195966 zhangzhf@gzhmu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.